Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.

@article{Blanger1988PlasmaLO,
  title={Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.},
  author={Alain B{\'e}langer and Marc Giasson and Johanne Couture and Andr{\'e} Dupont and Leonello Cusan and Fernand Labrie},
  journal={The Prostate},
  year={1988},
  volume={12 1},
  pages={79-84}
}
The present study describes a method for the measurement of the plasma levels of hydroxy-flutamide (Flu-OH), the biologically active and main circulating metabolite of flutamide. We have observed that two to four hours after oral administration of 250 mg of flutamide to healthy young men, as well as to patients with prostate cancer, the plasma concentration of Flu-OH reaches a peak at approximately 1.7 microM. The plasma concentration of Flu-OH measured at months 6, 12, and 18 of treatment… CONTINUE READING